Association of hyponatremia and hyperglycemia with outcome in dogs with congestive heart failure

Journal of Veterinary Emergency and Critical Care

Volumn 14, Issue 3, 2004, Pages 177-182

  Brady, Colleen A ^a   Hughes, Dez ^b   Drobatz, Kenneth J ^c  

^a Pacific Veterinary Specialists   (United States)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c Department of Clinical Studies ^*  (United States)

Author keywords

Canine; Chronic valvular disease; Dilated cardiomyopathy; Plasma glucose; Plasma sodium

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPONATREMIA; MALE; NONHUMAN; OUTCOMES RESEARCH; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ANIMALIA; CANIS FAMILIARIS;

EID: 13444300994     PISSN: 14793261     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1534-6935.2004.00118.x     Document Type: Article

References (44)

1. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohormonal activation and regional vascular resistance. Circulation 1987; 75(Suppl):IV-36-IV-38.
2. Kircheim HR, Just A, Ehmke H. Physiology and pathophysiology of baroreceptor function and neuro-hormonal abnormalities in heart failure. Basic Res Cardiol 1998; 93(Suppl):1-22.
3. Marin J, Marin E, Iniguez AG, et al. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment. Pharmacol Ther 2000; 88:15-31.
4. Haggstrom J, Hansson K, Karlberg BE, et al. Plasma concentrations of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res 1994; 55:698-703.
5. Tidholm A, Haggstrom J, Hansson K. Effects of dilated cardiomyopathy on the rennin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormones concentrations in dogs. Am J Vet Res 2001; 62(6):961-967.
6. Travill CM, Williams TD, Pate P. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res 1992; 26(8):783-790.
7. Nakamura M, Yoshida H, Funakoshi T, et al. Renal, hemodynamic, and hormonal interactions between atrial natriuretic peptide and arginine vasopressin in patients with congestive heart failure. Clin Sci 1992; 82:363-368.
8. Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998; 449:415-426.
9. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Eng J Med 1981; 305(5):263-266.
10. Wong BP, Wong NL. Renal hypersensitivity to vasopressin in congestive heart failure. Cardiology 1998; 90(1):20-27.
11. Levin ER, Gardner DG, Samson WK. Mechanisms of disease: natriuretic peptides. N Eng J Med 1998; 339(5): 321-328.
12. Light DB, Schweibert EM, Karlson KH, et al. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science 1989; 243:383-385.
13. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996; 156(16):1814-1820.
14. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73(2):257-267.
15. Cobb M, Michell A. Plasma electrolyte concentrations in dogs receiving diuretic therapy for cardiac failure. J Small Anim Pract 1992; 33:526-529.
16. Ware WA, Lund DD, Subieta AR, et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990; 197(11):1475-1481.
17. Tidholm A, Jonnson L. A retrospective study of canine dilated cardiomyopathy (189 cases). J Am Anim Hosp Assoc 1997; 33:544-550.
18. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: an overview. Lancet 2000; 355:773-778.
19. Norhammer A, Ryden L, Malmberg K. Admission plasma glucose: independent risk factor for long term prognosis after myocardial infarction even in non-diabetic patients. Diabetes Care 1999; 22(11):1827-1831.
20. Paolisso G, Tagliamonte M, Rizzo M, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral valve and/or aortic valve disease. Am J Cardiol 1999; 83:1338-1344.
21. Bellodi G, Manicardi V, Malavasi V. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989; 64(14):885-888.
22. Calvert CA, Pickus CW, Jacobs GJ, et al. Signalment, survival and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Intern Med 1997; 11(6):323-326.
23. Calvert CA, Hall G, Jacobs G, et al. Clinical and pathologic findings in Doberman Pinschers with occult cardiomyopathy that died suddenly or developed congestive heart failure: 54 cases. J Am Vet Med Assoc 1997; 210(4):505-511.
24. Monnet E, Orton EC, Saman M, et al. Idiopathic dilated cardiomyopathy in dogs: survival and prognostic indicators. J Vet Intern Med 1995; 9(1):12-17.
25. Panciroli C, Galloni G, Oddone A, et al. Prognostic value of hyponatremia in patients with severe chronic heart failure. Angiology 1990; 41(8):631-638.
26. Brooks VL, Osborn JW. Hormonal-sympathetic interactions in long-term regulation of arterial pressure: an hypothesis. Am J Physiol 1995; 268:R1343-R1358.
27. Manthey J, Dietz R, Opherk D, et al. Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness. Am J Cardiol 1992; 70:224-228.
28. Goldsmith SR. Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1992; 19:1180-1184.
29. Packer M, Lee W, Kessler P, et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987; 75(Suppl IV):IV-80.
30. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001; 51:372-390.
31. Hasser EM, Bishop VS, Hay M. Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Clin Exp Pharmacol Physiol 1997; 24(1): 102-108.
32. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994; 267:H2245-H2254.
33. Mulinari R, Gavras I, Wang Y, et al. Effects of a vasopressin antagoinist in rats with left ventricular dysfunction. Circulation 1990; 81:308-311.
34. Yatsu T, Tomura Y, Tahara A, et al. Pharmocologic profile of YM087, a novel nonpeptide dual vasopressin receptor antagonist, in dogs. Eur J Pharmacol 1997; 321:225-230.
35. Stone CK, Liang CS, Imai S, et al. Short term hemodynamic effects of vasopressin V1 receptor inhibition in chronic right sided congestive heart failure. Circulation 1988; 78:1251-1259.
36. Suskin N, McKelvie R, Burn R, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21(16):1368-1375.
37. Friehs I, Moran A, Stamm C, et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 1999; 100(19 Suppl):II187-II193.
38. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30(2):527-532.
39. Freeman LM, Rush JE, Brown DH, et al. Elevated concentrations of tumor necrosis factor in dogs with congestive heart failure. J Vet Intern Med 1994; 8:146.
40. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrythmias. Lancet 1994; 343:155-158.
41. Freeman LM, Rush JE, Kehayias J, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998; 12:440-448.
42. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992; 26:913-922.
43. Anker SD, Swan JW, Chin TP, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance for cardiac cachexia. Circulation 1997; 96(2):526-534.
44. De Franzo RA. The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologica 1981; 1:165-171.